Clinical characteristics of AML with RS phenotype
| . | All RS cases . | 1%-4% RS . | 5%-14% RS . | ≥15% RS . |
|---|---|---|---|---|
| Total | 126 | 53 (42) | 28 (22) | 45 (36) |
| Age, y | ||||
| Median | 67 | 67 | 63 | 70 |
| Range | 32-87 | 40-81 | 32-78 | 43-87 |
| Sex | ||||
| Male | 84 (67) | 32 (60) | 20 (71) | 32 (71) |
| Female | 42 (33) | 21 (40) | 8 (29) | 13 (29) |
| Type of disease | ||||
| de novo AML | 70 (56) | 35 (66) | 12 (43) | 23 (51) |
| sAML | 20 (16) | 6 (11) | 8 (29) | 6 (13) |
| t-MN | 17 (14) | 7 (13) | 3 (11) | 7 (16) |
| Other | 19 (15) | 5 (9) | 5 (18) | 9 (20) |
| WHO diagnosis | ||||
| AML with MDS-related changes | 47 (37) | 14 (26) | 16 (57) | 17 (38) |
| AML NOS | 24 (19) | 13 (25) | 3 (11) | 8 (18) |
| t-MN | 17 (14) | 7 (13) | 3 (11) | 7 (16) |
| MDS-EB2 | 17 (14) | 5 (9) | 4 (14) | 8 (18) |
| AML with recurrent abnormalities | 16 (13) | 13 (25) | 1 (4) | 2 (4) |
| Other | 5 (4) | 1 (2) | 1 (4) | 3 (7) |
| ELN risk score | ||||
| Favorable | 12 (10) | 11 (21) | 1 (4) | 0 (0) |
| Intermediate | 8 (6) | 4 (8) | 2 (7) | 2 (1) |
| Intermediate* | 29 (23) | 17 (32) | 5 (18) | 9 (20) |
| Adverse | 74 (59) | 21 (40) | 19 (67) | 34 (76) |
| Unknown | 3 (2) | 0 (0) | 1 (4) | 2 (4) |
| BM blasts, % | ||||
| Median | 32 | 34 | 24 | 32 |
| Range | 10-91 | 10-88 | 11-88 | 10-91 |
| Erythroblasts, % | ||||
| Median | 21 | 23 | 21 | 17 |
| Range | 1-64 | 4-64 | 2-50 | 1-59 |
| . | All RS cases . | 1%-4% RS . | 5%-14% RS . | ≥15% RS . |
|---|---|---|---|---|
| Total | 126 | 53 (42) | 28 (22) | 45 (36) |
| Age, y | ||||
| Median | 67 | 67 | 63 | 70 |
| Range | 32-87 | 40-81 | 32-78 | 43-87 |
| Sex | ||||
| Male | 84 (67) | 32 (60) | 20 (71) | 32 (71) |
| Female | 42 (33) | 21 (40) | 8 (29) | 13 (29) |
| Type of disease | ||||
| de novo AML | 70 (56) | 35 (66) | 12 (43) | 23 (51) |
| sAML | 20 (16) | 6 (11) | 8 (29) | 6 (13) |
| t-MN | 17 (14) | 7 (13) | 3 (11) | 7 (16) |
| Other | 19 (15) | 5 (9) | 5 (18) | 9 (20) |
| WHO diagnosis | ||||
| AML with MDS-related changes | 47 (37) | 14 (26) | 16 (57) | 17 (38) |
| AML NOS | 24 (19) | 13 (25) | 3 (11) | 8 (18) |
| t-MN | 17 (14) | 7 (13) | 3 (11) | 7 (16) |
| MDS-EB2 | 17 (14) | 5 (9) | 4 (14) | 8 (18) |
| AML with recurrent abnormalities | 16 (13) | 13 (25) | 1 (4) | 2 (4) |
| Other | 5 (4) | 1 (2) | 1 (4) | 3 (7) |
| ELN risk score | ||||
| Favorable | 12 (10) | 11 (21) | 1 (4) | 0 (0) |
| Intermediate | 8 (6) | 4 (8) | 2 (7) | 2 (1) |
| Intermediate* | 29 (23) | 17 (32) | 5 (18) | 9 (20) |
| Adverse | 74 (59) | 21 (40) | 19 (67) | 34 (76) |
| Unknown | 3 (2) | 0 (0) | 1 (4) | 2 (4) |
| BM blasts, % | ||||
| Median | 32 | 34 | 24 | 32 |
| Range | 10-91 | 10-88 | 11-88 | 10-91 |
| Erythroblasts, % | ||||
| Median | 21 | 23 | 21 | 17 |
| Range | 1-64 | 4-64 | 2-50 | 1-59 |
Data denoted as n (%), unless otherwise stated.
MDS-EB2, myelodysplastic syndrome with excess blasts type 2; NOS, not otherwise specified; sAML, secondary AML; t-MN, therapy-related myeloid neoplasm; WHO, World Health Organization.
*No evaluation for ASXL1, RUNX1, and TP53.